At the news
? BULLISHIMPACT 7/10 6-K filed Jun 29, 2026 at 16:24 ET
Genmab announced positive topline Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, meeting the primary endpoint with statistically significant improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40) and 56% (HR 0.44) under different censoring rules, with safety consistent with individual agents. This is a major clinical win that supports label expansion and strengthens epcoritamab's position as a core therapy in B-cell malignancies.
- Phase 3 EPCORE DLBCL-4 trial met primary endpoint with statistically significant improvement in PFS
- Risk reduction of 60% (HR 0.40, 95% CI 0.30-0.55, p<0.0001) in the U.S. and 56% (HR 0.44, 95% CI 0.33-0.60, p<0.0001) outside the U.S.
- Safety profile of epcoritamab plus lenalidomide consistent with known profiles of individual agents
- Genmab and AbbVie will engage global regulatory authorities for potential label expansion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access